SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Fundamental Analysis & Valuation

FRA:1SXP • DE000A3ENQ51

14.06 EUR
-0.48 (-3.3%)
Last: Mar 3, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This 1SXP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 1SXP. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. 1SXP.DE Profitability Analysis

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • In the past year 1SXP had a positive cash flow from operations.
  • 1SXP had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 1SXP had a positive operating cash flow.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • 1SXP has a Return On Assets of 9.26%. This is amongst the best in the industry. 1SXP outperforms 83.33% of its industry peers.
  • 1SXP has a better Return On Equity (16.21%) than 88.89% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 12.84%, 1SXP belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is above the industry average of 9.64%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • 1SXP has a Profit Margin of 15.13%. This is in the better half of the industry: 1SXP outperforms 77.78% of its industry peers.
  • 1SXP's Profit Margin has improved in the last couple of years.
  • 1SXP has a Operating Margin of 19.08%. This is in the better half of the industry: 1SXP outperforms 77.78% of its industry peers.
  • In the last couple of years the Operating Margin of 1SXP has grown nicely.
  • Looking at the Gross Margin, with a value of 33.68%, 1SXP is doing worse than 61.11% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1SXP.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1SXP is still creating some value.
  • Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
  • Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
  • The debt/assets ratio for 1SXP has been reduced compared to a year ago.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • 1SXP has a debt to FCF ratio of 7.05. This is a slightly negative value and a sign of low solvency as 1SXP would need 7.05 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 7.05, 1SXP perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • 1SXP has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.08, 1SXP belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.43
WACC8.98%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.58 indicates that 1SXP should not have too much problems paying its short term obligations.
  • 1SXP has a Current ratio of 1.58. This is in the better half of the industry: 1SXP outperforms 61.11% of its industry peers.
  • A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.17, 1SXP is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 1SXP.DE Growth Analysis

3.1 Past

  • The earnings per share for 1SXP have decreased by -2.02% in the last year.
  • Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.78% on average per year.
  • Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 4.39% in the last year.
  • Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.31% on average over the next years.
  • Based on estimates for the next years, 1SXP will show a small growth in Revenue. The Revenue will grow by 5.23% on average per year.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y7.31%
Revenue Next Year2.19%
Revenue Next 2Y4.57%
Revenue Next 3Y5.29%
Revenue Next 5Y5.23%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. 1SXP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 14.49, 1SXP is valued correctly.
  • Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 83.33% of the companies listed in the same industry.
  • 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
  • 1SXP is valuated correctly with a Price/Forward Earnings ratio of 12.40.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 94.44% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.95, 1SXP is valued rather cheaply.
Industry RankSector Rank
PE 14.49
Fwd PE 12.4
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 1SXP is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
  • 1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 66.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 178.29
EV/EBITDA 8.2
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)4.87
PEG (5Y)1.05
EPS Next 2Y8.11%
EPS Next 3Y9.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 1SXP.DE Dividend Analysis

5.1 Amount

  • 1SXP has a Yearly Dividend Yield of 1.21%.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.44. 1SXP pays more dividend than 94.44% of the companies in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.82, 1SXP is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.21%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 15.99% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP15.99%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1SXP.DE Fundamentals: All Metrics, Ratios and Statistics

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (3/3/2026, 7:00:00 PM)

14.06

-0.48 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.12B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts75.79
Price Target19.93 (41.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.21%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.13%
PT rev (3m)-32.63%
EPS NQ rev (1m)2.59%
EPS NQ rev (3m)-19.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.62%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-5.82%
Revenue NY rev (1m)-1.91%
Revenue NY rev (3m)-6.55%
Valuation
Industry RankSector Rank
PE 14.49
Fwd PE 12.4
P/S 2.12
P/FCF 178.29
P/OCF 13.32
P/B 2.28
P/tB 2.35
EV/EBITDA 8.2
EPS(TTM)0.97
EY6.9%
EPS(NY)1.13
Fwd EY8.06%
FCF(TTM)0.08
FCFY0.56%
OCF(TTM)1.06
OCFY7.51%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)4.87
PEG (5Y)1.05
Graham Number11.61
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC8.98%
ROIC/WACC1.43
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y7.31%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.19%
Revenue Next 2Y4.57%
Revenue Next 3Y5.29%
Revenue Next 5Y5.23%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.27%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 5 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.